US equities |
NVDA $236.83 ▲+1.23% SPCX $165.37 ▲+4.03% MU $1,064.13 ▼-1.00% TSLA $377.87 ▲+1.96% MSFT $526.42 ▲+1.72% INTC $116.62 ▼-2.27% SNDK $1,722.49 ▲+0.15% AMD $627.90 ▼-0.95%
FinancialContent

Veracyte, Inc. - Common Stock (NQ:VCYT)

45.73 -0.09 (-0.19%)
Delayed Quote Updated: 10:09 AM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Veracyte, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Veracyte Inc (NASDAQ:VCYT) GARP Analysis Reveals Strong Growth at a Reasonable Price ↗
Via Chartmill
Veracyte Inc (NASDAQ:VCYT): A High-Growth Biotech Stock Poised for a Technical Breakout ↗
Via Chartmill
News headline image
Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers
From Veracyte, Inc.
Via Business Wire
Curious about the stocks that are showing activity after the closing bell on Thursday? ↗
Via Chartmill
Veracyte Inc (NASDAQ:VCYT) Emerges as a Prime Growth at a Reasonable Price (GARP) Candidate ↗
Via Chartmill
Veracyte Inc (NASDAQ:VCYT) Posts Strong Q4 Earnings Beat and Positive 2026 Outlook ↗
Via Chartmill
Topics Earnings
Veracyte Inc (NASDAQ:VCYT): A Prime GARP Stock with Strong Growth and a Sound Balance Sheet ↗
Via Chartmill
Veracyte Inc. (NASDAQ:VCYT) Emerges as a Prime Affordable Growth Candidate ↗
Via Chartmill
News headline image
Earnings Scheduled For November 4, 2025 ↗
 
Via Benzinga
News headline image
Veracyte to Release First Quarter 2026 Financial Results on May 5, 2026
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Names Kevin Haas as Chief Development and Technology Officer
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte (VCYT) Q4 2025 Earnings Call Transcript ↗
Veracyte (VCYT) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Veracyte Announces Fourth Quarter and Full Year 2025 Financial Results
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Highlight Extensive Decipher® Data at 2026 ASCO GU Symposium
From Veracyte
Via Business Wire
News headline image
Veracyte to Participate in Upcoming Investor Conferences
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Release Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026
From Veracyte, Inc.
Via Business Wire
News headline image
Biodesix Shares Rocket 42% on Record FY2025 Results and Path to Profitability
On January 12, 2026, the diagnostic sector witnessed a seismic shift as shares of Biodesix (Nasdaq: BDSX) surged more than 40% in early trading, following the release of preliminary full-year 2025... 
Via MarketMinute
Topics Artificial Intelligence Death
News headline image
Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Participate in the 44th Annual J.P. Morgan Healthcare Conference
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Inc (NASDAQ:VCYT) Emerges as a Top Affordable Growth Stock ↗
Veracyte (VCYT) exemplifies the GARP strategy, offering strong growth, a reasonable industry price, and a solid debt-free financial foundation. 
Via Chartmill
News headline image
Veracyte Inc (NASDAQ:VCYT): A GARP Stock With Strong Growth and a Reasonable Price ↗
Veracyte (VCYT) exemplifies GARP investing with strong cancer diagnostic growth, reasonable valuation vs. biotech peers, and a debt-free financial foundation. 
Via Chartmill
News headline image
Veracyte to Participate in Upcoming Investor Conferences
From Veracyte, Inc.
Via Business Wire
News headline image
Johnson Controls, Babcock & Wilcox, Lemonade, Lumentum, Teva Pharmaceutical And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Veracyte Announces Third Quarter 2025 Financial Results
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Inc (NASDAQ:VCYT): An Affordable Growth Candidate in Biotech ↗
Veracyte (VCYT) offers affordable growth with strong earnings, a solid balance sheet, and reasonable valuation in the biotech sector. 
Via Chartmill
News headline image
Veracyte to Release Third Quarter 2025 Financial Results on November 4, 2025
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces First Publications Using Afirma GRID Research Tool To Help Usher in Next Generation of Thyroid Nodule Testing
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Inc (NASDAQ:VCYT) Presents a Strong Growth and Breakout Opportunity ↗
Veracyte (VCYT) stock analysis shows strong growth potential with 20% revenue growth, zero debt, and a bullish technical setup for a breakout. 
Via Chartmill
News headline image
Veracyte Inc (NASDAQ:VCYT): An Affordable Growth Candidate in Cancer Diagnostics ↗
Veracyte (VCYT) offers affordable growth with strong revenue & earnings expansion, a solid debt-free balance sheet, and reasonable valuation for the biotech sector. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >